紫杉醇是目前應(yīng)用最為廣泛的抗腫瘤藥物之一，主要通過(guò)穩(wěn)定微管和抑制微管解聚而阻滯細(xì)胞周期、誘導(dǎo)細(xì)胞凋亡等機(jī)制殺滅癌細(xì)胞，臨床主要用于卵巢癌、乳腺癌、非小細(xì)胞肺癌、卡波式肉瘤等多種腫瘤性疾病的治療。隨著研究的深入，發(fā)現(xiàn)紫杉醇對(duì)于諸如血管性疾病、肺動(dòng)脈高壓、纖維增生性疾病、炎癥性疾病和神經(jīng)損傷性疾病等非腫瘤性疾病的治療具有一定的應(yīng)用前景。主要對(duì)紫杉醇在非腫瘤性疾病中的研究進(jìn)展進(jìn)行綜述，為開(kāi)拓紫杉醇的臨床應(yīng)用提供參考。

Paclitaxel, one of the broadest application anticancer agents, is currently used for the treatment of different types of cancers, such as metastatic breast cancer, advanced ovarian cancer, non-small-cell lung cancer, and Kaposi's sarcoma. It is acknowledged that paclitaxel kills cancer cells through the arresting cell cycle and inducing cell death by stabilizing microtubules and interfering with microtubule disassembly. However, recent studies have demonstrated that paclitaxel has some application prospects in non-neoplastic diseases such as vascular disease, pulmonary arterial hypertension, fibrosis disease, inflammatory disease, and nerve injury disease. Research progress on application of paclitaxel in non neoplastic diseases is reviewed in this paper, which may provide a reference for further clinical application of paclitaxel.